A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Washington University researchers find a vaccine that shows promise against aggressive breast cancer. KMOX Health Editor Fred ...

An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

University of Zagreb researcher Beata Halassy treated her breast cancer with an unproven virus-based therapy using viruses ...